Saturday, October 3, 2026

Apollo Raised NOVO BANCO Bid But Fosum and Anbang Offers Are Still in the Race

Banco de Portugal confirmed Apollo Global Management raised its bid for Novo Banco in August 2015, while Chinese competitors Fosun and Anbang held their offers. The sale of Portugal's third-largest bank carried major implications for the country's banking resolution fund.

LM Salvado
LM Salvado

August 12, 2015

Novo Banco - Image Credit João Ramos

Banco de Portugal, the institution overseeing the sale of Novo Banco, confirmed in August 2015 that American private equity firm Apollo Global Management increased its bid for the troubled Portuguese lender. The two other contenders—Chinese conglomerates Fosun International and Anbang Insurance Group—did not raise their offers.

Novo Banco, Portugal's third-largest bank by assets, was created in August 2014 as a "good bank" successor to Banco Espírito Santo following its collapse. The state-backed rescue isolated toxic assets linked to the founding Espírito Santo family's debts, with the resolution funded by Portugal's banking sector.

While Apollo improved its offer, sources familiar with the negotiations indicated that Anbang's bid remained the highest among the three finalists. The exact terms of each proposal were not disclosed by the regulator.

Banco de Portugal stated it expected to reach a final decision in the coming weeks. The outcome carried significant implications for Portugal's financial system: any shortfall from the sale would be borne by the Portuguese banks' resolution fund, potentially requiring additional contributions from the country's banking sector.

Editor's note: This article was originally published in August 2015. The Novo Banco sale process ultimately concluded in October 2017, when Lone Star Funds acquired a 75% stake in the bank.

LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com